MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$35,148K
EPS
-$1.16
Unit: Thousand (K) dollars

Income Statement
2025-12-31
Research and development
24,769
General and administrative
13,340
Total operating expenses
38,109
Loss from operations
-38,109
Interest income
2,934
Other income
1
Net loss attributable to common stockholders
-35,174
Unrealized gain (loss) on investments
26
Comprehensive loss
-35,148
Basic EPS
-1.16
Diluted EPS
-1.16
Basic Average Shares
30,215,747
Diluted Average Shares
30,215,747
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$35,148K Unrealized gain (loss) oninvestments$26K Net lossattributable to common...-$35,174K Interest income$2,934K Other income$1K Loss from operations-$38,109K Total operatingexpenses$38,109K Research and development$24,769K General andadministrative$13,340K

AN2 Therapeutics, Inc. (ANTX)

AN2 Therapeutics, Inc. (ANTX)